Drug Index



Mechanism :

Dalbavancin is a lipoglycopeptide which binds to the D-alanyl-D-alanine terminus of the stem pentapeptide in nascent cell wall peptidoglycan, preventing cross-linking and interfering with cell wall synthesis. It is bactericidal in vitro against Staphylococcus aureus and Streptococcus pyogenes.

Indication :

• Acute bacterial skin and skin structure infections due to gram positive organisms

Contraindications :

Hypersensitivity to dalbavancin or any component of the formulation.

Dosing :

Safety and efficacy not established in pediatric population.

Adults: 1 dose regime of 1500 mg IV or give 1000 mg IV in 2 doses followed by 500 mg after 1 week.

Adverse Effect :

Flushing, headache, skin rash, hypoglycaemia, increased GGT, nausea, diarrhea, GIT haemorrhage, acute post-hemorrhagic anemia, hepatotoxicity, increased serum alkaline phosphatase, anaphylactoid reaction, infusion related reaction including red-man syndrome.

Interaction :

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol.
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.

01/30/2020 06:12:05 Dalbavancin
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0